Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 14 2017 - 4:02PM
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company
focused on developing novel oncology and hematology therapeutics,
today announced that management will be presenting at the 29th
Annual Piper Jaffray Healthcare Conference on Tuesday, November 28,
2017 at 4:00 pm ET at the Lotte New York Palace Hotel.
A live audio webcast of the presentation can be
accessed at www.aptevotherapeutics.com under the ‘Investors’
section of the website, under ‘Events.’ An audio reply of the
webcast will be available approximately 2 hours following the live
webcast.
About Aptevo Therapeutics
Inc.
Aptevo Therapeutics Inc. is a clinical-stage
biotechnology company focused on novel oncology and hematology
therapeutics to meaningfully improve patients’ lives. Aptevo has a
commercial product, IXINITY® coagulation factor IX (recombinant),
approved and marketed in the United States for the treatment of
Hemophilia B, and a versatile core technology – the ADAPTIR™
modular protein technology platform capable of generating
highly-differentiated bispecific antibodies with unique mechanisms
of action to treat cancer and autoimmune diseases. Aptevo has two
ADAPTIR antibody candidates currently in clinical development and a
broad pipeline of novel investigational-stage bispecific antibody
candidates focused in immuno-oncology and autoimmune disease and
inflammation. For more information, please visit
www.aptevotherapeutics.com.
Source:
Aptevo Therapeutics Stacey Jurchison Senior
Director, Investor Relations and Corporate Communications
206-859-6628 JurchisonS@apvo.com
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Apr 2023 to Apr 2024